24 May 2018 12:12
Tissue Regenix Group plc
Result of AGM
Leeds, 24 May 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company provides notification that at the Group's AGM held earlier today, all resolutions were duly proposed to shareholders and passed.
For more Information:
Tissue Regenix Group plc Caitlin Pearson Head of Communications | Tel: 0330 430 3073 / 07920272 441 |
|
|
Jefferies International Ltd Simon Hardy / Christopher Binks | Tel: 020 7029 8000
|
|
|
FTI Consulting Brett Pollard / Mo Noonan/ Mary Whittow | Tel: 0203 727 1000 |
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.
Tissue Regenix Group (TRX)